



Effects of Adipose-derived Stem Cells in the Treatment of Knee Osteoarthritis: A Case Report in Brazil's Unified Health System

Efeitos das células-tronco mesenquimais no tratamento da osteoartrite de joelho: um relato de caso no Sistema Único de Saúde do Brasil

Laynna de Carvalho Schweich-Adami^{1,2} Roberto Antonioli da Silva³ Adivanio Baranoski¹
Candida Aparecida Leite Kassuya⁴ Andréia Conceição Milan Brochado Antonioli-Silva^{1,2}
Rodrigo Juliano Oliveira^{1,2,5}

¹ Centro de Estudos em Células Tronco, Terapia Celular e Genética Toxicológica – CeTroGen, Hospital Universitário Maria Aparecida Pedrossian – HUMAP/EBSEH, Universidade Federal de Mato Grosso do Sul – UFMS, Campo Grande, Mato Grosso do Sul, MS, Brasil

² Programa de Pós-graduação em Saúde e Desenvolvimento da Região Centro-Oeste, Faculdade de Medicina Dr. Hélio Mandetta – FAMED, Universidade Federal de Mato Grosso do Sul – UFMS, Campo Grande, Mato Grosso do Sul, MS, Brasil

³ Ambulatório de Ortopedia e Traumatologia, Hospital Universitário Maria Aparecida Pedrossian – HUMAP/EBSEH, Universidade Federal de Mato Grosso do Sul – UFMS, Campo Grande, Mato Grosso do Sul, MS, Brasil

Address for correspondence Rodrigo Juliano Oliveira, PhD, Faculdade de Medicina, Universidade Federal de Mato Grosso do Sul, Cidade Universitária s/n, Campo Grande, Mato Grosso do Sul, MS, 79070-900, Brasil (e-mail: rodrigo.oliveira@ufms.br).

⁴ Faculdade de Ciências da Saúde – FCS, Universidade Federal da Grande Dourados – UFGD, Dourados, Mato Grosso do Sul, MS, Brasil

⁵ Programa de Pós-Graduação em Genética e Biologia Molecular, Centro de Ciências Biológicas – CCB, Universidade Estadual de Londrina – UEL, Londrina, Paraná, PR, Brasil

Rev Bras Ortop

Abstract

Osteoarthritis (OA) can incapacitate the individual to perform their activities of daily living due to pain. This is an important public health issue that worsens worldwide and in Brazil, since the population goes through an aging process, and has caused increased public spending on the monitoring and maintenance of treatments that can last for years and still not be resolute. Thus, the search for innovative and effective therapies that can reduce costs becomes necessary. In this context, the present study reports the first application of cell therapy with adipose-derived stem cells in the treatment of cases of OA that are refractory to the conservative treatment, performed in the Brazilian Unified Health System (Sistema Único de Saúde, SUS). The evaluation was performed with the application of the Visual Analog Scale (VAS), the Short Form Health Survey (SF-36) and the Western Ontario and McMaster Universities (WOMAC), specifics for OA evaluation, and also an analysis of the synovial fluid (inflammatory cytokines). The cell therapy improved the scores on the WOMAC, SF-36 and EVA, and reduced the inflammatory process. We observed a decrease of 0.73x in the TNF, of 0,71x in

Keywords

- ▶ cell therapy
- ▶ joint pain
- ▶ inflammation
- ▶ Unified Health System
- ▶ orthopedics
- ▶ regenerative medicine

received
October 29, 2020
accepted
February 11, 2021

DOI <https://doi.org/10.1055/s-0041-1733797>.
ISSN 0102-3616.

© 2021. Sociedade Brasileira de Ortopedia e Traumatologia. All rights reserved.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (<https://creativecommons.org/licenses/by-nc-nd/4.0/>)

Thieme Revinter Publicações Ltda., Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

IL-1b, of 0,68x in IL-8, and of 0,70x in IL-10. For IL-6, an increase of 1,48x was observed. Therefore, this cell therapy can be considered promising in aiding the management of this disease, since it improved the patient's pain, decrease inflammatory markers, and enabled the return to activities of daily living, which resulted in an improvement in their quality of life.

Resumo

A osteoartrite (OA) pode deixar o indivíduo incapacitado para realizar suas atividades da vida diária devido ao quadro álgico. Essa é uma importante questão de saúde pública que se agrava no mundo inteiro e no Brasil, uma vez que a população passa pelo processo de envelhecimento, e isso causa um aumento nos gastos públicos com o acompanhamento e manutenção dos tratamentos que podem perdurar por anos e mesmo assim não serem resolutivos. Assim, torna-se necessária a busca por terapias inovadoras e eficazes que possam reduzir esses custos. Nesse contexto, o presente estudo relata a primeira aplicação de terapia celular com células-tronco mesenquimais do tecido adiposo no tratamento de OA refratária ao tratamento conservador realizada no Sistema Único de Saúde (SUS). Na avaliação, foram usados os instrumentos Escala Visual Analógica (EVA), os questionários de qualidade de vida Short Form Health Survey (SF-36) e Western Ontario and McMaster Universities (WOMAC), específicos para avaliação da OA, e fez-se uma análise do líquido sinovial (citocinas inflamatórias). A terapia celular melhorou as pontuações no WOMAC, SF-36, e EVA, e reduziu o processo inflamatório. Observou-se redução de 0,73x do TNF, de 0,71x da IL-1b, de 0,68x da IL-8, e de 0,70x da IL-10. Já para a IL-6, observou-se aumento de 1,48x. Portanto, considera-se a terapia celular promissora no auxílio do manejo desta doença, pois melhorou o quadro álgico do paciente, reduziu os marcadores inflamatórios, e possibilitou o retorno às atividades da vida diária, o que resultou em uma melhora de sua qualidade de vida.

Palavras-chave

- ▶ terapia celular
- ▶ dor articular
- ▶ inflamação
- ▶ Sistema Único de Saúde
- ▶ ortopedia
- ▶ medicina regenerativa

Introduction

Adipose-derived stem cells (ADSCs) have interesting results in the treatment of osteoarthritis (OA).¹ Our preclinical results indicated that ADSCs, by paracrine effect and cell differentiation, can lead to improved repair and regeneration of cartilage.² These data were important to start a clinical study which will use ADSCs in the treatment of OA in humans, and to implement innovative therapies at the Cell Processing Center, in partnership with the Orthopedics Service at University Hospital Maria Aparecida Pedrossian (HUMAP/EBSERH), in the city of Campo Grande, state of Mato Grosso do Sul (MS), Brazil.

The present study reports the results of the first cell therapy with ADSCs in a patient of the Brazilian Unified Health System (Sistema Único de Saúde, SUS).

Case report

A male patient, aged 66 years, weighing 93 kg, and 1,75m, with a diagnosis of medial meniscus rupture in the right knee, with grade III OA (in the Kellgreen and Lawrence classification through radiographic evaluation), and total prosthesis in the left knee. In the clinical evaluation, he reported intermittent pain in the right knee, presented joint

cracking with movement, increased knee circumference, and decreased range of motion (ROM), only being able to flex the leg up to 95° without feeling pain. During the interview, we applied the Visual Analog Scale (VAS), the Short Form Health Survey (SF-36), and the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index. The patient was then informed about the treatment with ADSCs and signed the free and informed consent form for the use of cell therapy.

The following week, a videoarthroscopy surgery was performed according to the routine of the Orthopedics Service (HUMAP/EBSERH) (► **Figure 1C-D**), was performed only cleaning of the joint and light debridement of the affected cartilage. After one week, the patient returned to the hospital for the collection of adipose tissue, a procedure performed by liposuction.³

Regarding of the liposuction processing, extraction, culture, characterization (immunophenotyping: CD105, CD90, CD34 and CD133), and cell differentiation (adipogenic, chondrogenic and osteogenic) were performed according to Schweich et al.⁴ (2017). The cultivation of ADSCs for transplantation occurred for 25 days (3rd passage), until reaching the necessary amount (► **Figure 2**).⁴ Bacteriological testing was performed before the cell therapy. Then, the patient returned and received an intra-articular injection containing




Fig. 1 Videarthroscopy surgical procedure. (A) Arthrocentesis. (B) Collected synovial fluid. (C) Positioning of the surgical instruments and entry sites. (D) Visualization of articular cartilage to clean debris or areas without leveling.

1×10^7 of ADSCs homogenized in 3 mL of saline solution (► **Figure 2**). A bandage was applied around the treated knee to avoid limb flexion in the first 12 hours.

The collection of synovial fluid occurred in two moments: in the operating room, before the videarthroscopy (► **Figure 1B**), and after six months of cell therapy. For the analysis of the inflammatory process, we used the CBA Human Inflammatory Cytokines KIT (BD Biosciences, Franklin Lakes, NJ, US), according to the manufacturer's instructions, by flow cytometry (Cytotflex, Beckman Coulter, Inc., Brea, CA, US).

Regarding the results of the cell therapy, we observed that, in the evaluation of the domains of the SF-36 questionnaire, functional capacity and limitation by physical aspects im-




Fig. 2 Flowchart of the procedures to obtain and process lipospiarte, cultivation of adipose-derived stem cells, and application in the knee with osteoarthritis.




Fig. 3 Values acquired after proposed evaluations, in the period before and after treatment with ADSCs. (A) Score of the SF-36 questionnaire applied before the intervention and after 6 months. (B) WOMAC questionnaire scores before the intervention, at the 3rd month and at the 6th month. (C) EVA classification performed before the intervention, in the 3rd month and in the 6th month. (D) Quantification of inflammatory cytokines before intervention and at the 6th month.

proved by 3x pain by 2,6x, social aspects by 2,5x, the emotional aspects by 2x, mental health by 1,4x and general health and vitality by 1.1x (► **Figure 3A**).

The WOMAC questionnaire indicated a reduction in the score of the domains in both evaluations at three and six months after the cell therapy. In the second evaluation, in relation to the initial condition, the decrease was 0,55x in pain intensity, 0,43x in stiffness, 0,84x for physical activity and 0,76x in the total score (► **Figure 3B**).

The EVA scale showed a decrease of 0,8x and 0,63x for the first (3 months) and second (6 months) assessments, respectively (► **Figure 3C**).

The macroscopic evaluation of the synovial fluid showed improved viscosity, reduction of opacity, and greater homogeneity. The evaluation of inflammatory cytokines showed a decrease of 0,73x of TNF, 0,71x of IL-1b, 0,68x of IL-8 and 0,70x of IL-10. In IL-6, an increase of 1.48x was observed (► **Figure 3D**).

Discussion

The way of action of ADSCs in the treatment of OA occurs through three different biological effects: cell differentiation, inflammatory modulation (paracrine effect) and mediation

of chondroprotectors.⁵ In the present report, the scores on the SF-36, WOMAC and EVA demonstrate that cell therapy can improve the condition of patients with OA, since it improves the functionality of the affected limb and the patient as a whole, which reflects in the return to activities of daily living and improvements in the overall quality of life, these results corroborate with the current literature.^{6,7}

In the pathogenesis of OA, the predominance of the IL-6, IL-1b and TNF cytokines stands out. These cytokines have the ability to activate multiple inflammatory pathways, and they may increase disease severity, joint swelling and cartilage destruction.⁸ In the present case report, a decrease in the levels of IL-1b, IL-8, IL-10, and mainly TNF, was also observed. With the reduction in these cytokines, it can be suggested that there was a decrease in the local inflammatory process, which aided in the improvement of the degenerative picture of this joint. However, with the specific decrease of IL-10, which is an anti-inflammatory cytokine,⁹ it is observed that there is a need for further studies that can describe/understand how ADSCs modulate the inflammatory process in this disease. The only cytokine that increased was IL-6, which is related to the activation of target genes involved in cell differentiation, proliferation and apoptosis.⁸ Thus, we infer this increase due to the mild debridement performed during the videoarthroscopy surgery, since it stimulates proliferation/differentiation.

The reduction in the inflammatory process, suggested by the modulation of cytokines, may explain the improvement in the viscosity of the synovial fluid, as well as the reduction in opacity, since the inflammatory process causes an influx of cells into the joint cavity. Therefore, with the reduction in the number of cells, there is a reduction in opacity. In addition to this, and to the increased homogeneity, we observed a reduction in fibrin and remnants of cartilage wear that are also favored by the inflammatory process that has been reduced.¹⁰ These facts are important, since the quality of the synovial liquid is an indicator of the quality of the articular cartilaginous tissue.

We conclude that cell therapy with ADSCs in patients with OA refractory to the conservative treatment can be considered a promising alternative in aiding in the management of this disease, since there is an improvement in pain, and return of the patient to their activities of daily living.

Conflict of interests

The authors have no conflict of interests to declare.

Acknowledgements

The authors would like to thank Dr. Tatyane Ferreira da Silva for the liposuction procedure, as well as FUNDECT, CNPq and CAPES for the financial support.

References

- 1 Biazzo A, D'Ambrosi R, Masia F, Izzo V, Verde F. Autologous adipose stem cell therapy for knee osteoarthritis: where are we now? *Phys Sportsmed* 2020;48(04):392-399
- 2 Hermeto LC, DeRossi R, Oliveira RJ, et al. Effects of intra-articular injection of mesenchymal stem cells associated with platelet-rich plasma in a rabbit model of osteoarthritis. *Genet Mol Res* 2016;15(03):10.4238/gmr.15038569
- 3 Pesarini JR, Oliveira RJ, Pessatto LR, et al. Vitamin D: Correlation with biochemical and body composition changes in a southern Brazilian population and induction of cytotoxicity in mesenchymal stem cells derived from human adipose tissue. *Biomed Pharmacother* 2017;91:861-871
- 4 Schweich LC, Oliveira EJT, Pesarini JR, et al. All-trans retinoic acid induces mitochondria-mediated apoptosis of human adipose-derived stem cells and affects the balance of the adipogenic differentiation. *Biomed Pharmacother* 2017;96:1267-1274
- 5 Lee WS, Kim HJ, Kim KI, Kim GB, Jin W. Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells for the treatment of knee osteoarthritis: a phase IIb, randomized, placebo-controlled clinical trial. *Stem Cells Transl Med* 2019;8(06):504-511
- 6 Lu L, Dai C, Zhang Z, et al. Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, doubleblind, active-controlled, phase IIb clinical trial. *Stem Cell Res Ther* 2019; 10(01):143
- 7 Pers YM, Rackwitz L, Ferreira R, et al; ADIPOA Consortium. Adipose Mesenchymal Stromal Cell-Based Therapy for Severe Osteoarthritis of the Knee: A Phase I Dose-Escalation Trial. *Stem Cells Transl Med* 2016;5(07):847-856
- 8 Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. *Nat Rev Immunol* 2010;10(03):170-181
- 9 Wang T, He C. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. *Cytokine Growth Factor Rev* 2018; 44:38-50
- 10 Franco RN, Cintra Neto PF, Pimentel ER, Cohen M, Lima GEG, Mattiello-Rosa SMG. Correlation between inflammatory cells and sulfated glycosaminoglycan concentration in synovial fluid of subjects with secondary knee osteoarthritis. *J Rheumatol* 2008; 35(06):1096-1101